Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2002

View Archived Issues

Antalarmin, a CRF1 antagonist, for the therapy of anxiety

SN-38 induces cell cycle arrest and apoptosis in human testicular cancer cells

Structure of FAAH elucidated

Arzoxifene and LG-100268 effective alone and in combination in a rat breast cancer model

Shigella vaccine is safe and immunogenic in phase I trial

Alliance and Mixture Sciences enter technology license agreement

Statistically significant preliminary results in Visudyne study in minimally classic wet AMD

Fujisawa expands topical Atrisone collaboration with Atrix

VaxGen and Kaketsuken sign agreement for smallpox vaccine development

Efficacy of alicaforsen reported in patients with active Crohn's disease

Antiarrhythmic action of a novel arylpiperazine RSD-992 shown in rats and guinea pigs

CP-461 well tolerated in a phase I trial in patients with advanced cancer

Phase II asthma trial of interferon gamma-1b completes randomization

Initial milestone achieved in Applied Molecular Evolution/Chiron collaboration

AVI BioPharma and International Therapeutics to develop NeuGene compounds for HIV

Drug pipeline for allergic rhinitis

BLA amendment for Xolair includes new data

Phase II trial of VX-148 in psoriasis patients commences in Iceland

Novel inhibitors of cytokine production covered by Boehringer Ingelheim patent

Aventis researchers design novel agents for in vitro and in vivo nucleic acid delivery

Decalactones of fungal origin reported to exhibit antitumor and antiinfective activity

New antithrombotic 5-thio-beta-D-xylopyranose derivatives under study at Fournier

Piperidine-based motilin agonists described by Solvay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...